The inaugural Commercializing Flow 91AV Summit is your catalyst to bridge the gap between using flow for a single step in R and D to supporting fully integrated GMP drug substance manufacturing, from technical, economic and regulatory standpoints.
Over the last few years, we have witnessed proven case studies from the likes of GSK, AbbVie, Bristol-Myers Squibb to employ flow chemistry in both drug discovery and development. With the benefits made possible by this technology, the flow chemistry market revenue is now expected to hit US$2.5 billion by 2026.
The CFC Summit will focus on continuous flow applications in both drug discovery and commercial manufacturing within pharma and biotech, from enabling drug discovery, improving safety profiles to easing of scale-up. With these benefits truly beginning to be realized in a commercial environment and by regulatory bodies, we are at a tipping point for the widespread adoption of flow chemistry in pharma and biotech.
This 3-days summit will be your unique platform this summer, whether you're looking to join the movement or stay ahead of the curve.
Over the last few years, we have witnessed proven case studies from the likes of GSK, AbbVie, Bristol-Myers Squibb to employ flow chemistry in both drug discovery and development. With the benefits made possible by this technology, the flow chemistry market revenue is now expected to hit US$2.5 billion by 2026.
The CFC Summit will focus on continuous flow applications in both drug discovery and commercial manufacturing within pharma and biotech, from enabling drug discovery, improving safety profiles to easing of scale-up. With these benefits truly beginning to be realized in a commercial environment and by regulatory bodies, we are at a tipping point for the widespread adoption of flow chemistry in pharma and biotech.
This 3-days summit will be your unique platform this summer, whether you're looking to join the movement or stay ahead of the curve.
